Informations générales (source: ClinicalTrials.gov)
Follow-up of Patients With Uveal Melanoma Adapted to the Risk of Relapse (SALOME) (SALOME)
Interventional
N/A
Institut Curie (Voir sur ClinicalTrials)
juillet 2020
juillet 2035
13 novembre 2024
Biomarkers search for early diagnosis of liver metastases in patients with uveal melanoma
who benefit from a follow-up tailored to their personalized risk of relapse.
Etablissements
| Les établissements d'Île-de-France ayant mis à jour leurs données Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| CLCC INSTITUT CURIE | 04/12/2024 12:44:21 | Contacter | |||
Critères
Tous
Inclusion Criteria:
1. Patient aged of 18 years or more.
2. Patient with uveal melanoma with high metastatic relapse risk defined as :
- T2b/c/d ou ≥ T3,
- or chromosom 3 or chromosom 8 abnormality by CGH array.
3. Completion of treatment of the primary tumor ≤ 2 months.
4. Patient able to comply with the schedule of visits and blood samples of the study.
5. Signed informed consent form or legal representative.
1. Patient aged of 18 years or more.
2. Patient with uveal melanoma with high metastatic relapse risk defined as :
- T2b/c/d ou ≥ T3,
- or chromosom 3 or chromosom 8 abnormality by CGH array.
3. Completion of treatment of the primary tumor ≤ 2 months.
4. Patient able to comply with the schedule of visits and blood samples of the study.
5. Signed informed consent form or legal representative.
1. Patient without french social insurance.
2. Any social, medical or psychological condition making the research process
impossible.